Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

New HIV therapy suppresses viral replication and increases immune cells in drug-resistant patients

New HIV therapy suppresses viral replication and increases immune cells in drug-resistant patients

Ebola outbreak in Congo spreads to active combat zone

Ebola outbreak in Congo spreads to active combat zone

FDA approves drug for rare, hard-to-treat types of non-Hodgkin lymphoma

FDA approves drug for rare, hard-to-treat types of non-Hodgkin lymphoma

Researchers characterize production process for standardized monoclonal antibody

Researchers characterize production process for standardized monoclonal antibody

Researchers engineer three cell lines to produce nonproprietary versions of NISTmAb

Researchers engineer three cell lines to produce nonproprietary versions of NISTmAb

European Commission approves Pfizer’s first oncology biosimilar

European Commission approves Pfizer’s first oncology biosimilar

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

CellMax Life receives six U.S. patents for early cancer detection blood test

CellMax Life receives six U.S. patents for early cancer detection blood test

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Omeros’ OMS721 receives positive opinion from EMA's COMP for treating hematopoietic stem cell transplant

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints

Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

New clinical trial to evaluate virotherapy and immunotherapy combination for ovarian, colorectal cancers

Ludwig-developed antibody drug for deadly brain cancer may have broader applications

Ludwig-developed antibody drug for deadly brain cancer may have broader applications

Atlantic Health System starts enrolling patients in four pancreatic cancer clinical trials

Atlantic Health System starts enrolling patients in four pancreatic cancer clinical trials

Study reveals new way to inhibit capillary leakage in sepsis

Study reveals new way to inhibit capillary leakage in sepsis

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Study finds increased risk of mortality in people with cold agglutinin disease in five years after diagnosis

Study finds increased risk of mortality in people with cold agglutinin disease in five years after diagnosis

Innovative drugs and new European treatment guidelines refine, improve MS therapy

Innovative drugs and new European treatment guidelines refine, improve MS therapy

Canakinumab reduces gout rate by more than half in atherosclerosis patients, study shows

Canakinumab reduces gout rate by more than half in atherosclerosis patients, study shows

Regeneron collaborates with Zoetis to research antibody therapies for animals

Regeneron collaborates with Zoetis to research antibody therapies for animals